



**Media Contacts:**

Corindus Vascular Robotics  
Tal Wenderow  
(508) 653-3335 ext. 205  
[Tal.Wenderow@corindus.com](mailto:Tal.Wenderow@corindus.com)

KNB Communications  
Brittney Quinn  
203-504-8230 ext. 134  
[corindus@knbpr.com](mailto:corindus@knbpr.com)

**Corindus Vascular Robotics Executive Participates in Forum Discussing  
Advancements in Human-Robotic Interaction**

*Corindus VP will lead discussion during Medical Development Group Forum on patient benefits of robotics, March 5*

**Waltham, MA, February 27, 2014**– [Corindus Vascular Robotics](#), a leading developer of precision vascular robotics, will participate in the upcoming Medical Development Group (MDG) forum focusing on advances in human-robotic interaction. Jerry Jennings, Vice President of Research and Development for Corindus, will be speaking at the March 5 forum about the interaction between humans and the CorPath system, and the benefits that vascular robotics provides. The forum will take place at Constant Contact in Waltham, Mass. beginning at 5:30 p.m.

In many settings, robots are designed to operate autonomously. In medical procedures, robots are designed to enhance the capabilities of the physician and assist by adding a level of robotic precision to the control of devices. The MDG interactive discussion, titled *Advances in Human-Robotic Interaction: Present and Future Impact on the Medical Field*, will address the latest advances in robotics in health care.

“As a leader in the medical robotics space, we are pleased to have the opportunity to participate in the MDG forum highlighting the critical elements in the interaction between the expert staff in the cardiac cath lab and the CorPath robot.” said Jennings. “At Corindus, we spent years designing our system to fit into the existing cath lab workflow, so that physicians can easily incorporate CorPath into their practice.”

The CorPath System is the first and only FDA-cleared technology that enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. During a CorPath Robotic Angioplasty procedure, the interventional cardiologist sits in the radiation shielded interventional cockpit. Using robotic precision, the interventional cardiologist advances stents and guidewires via a joystick with millimeter by millimeter precision. CorPath may improve clinical outcomes by enabling precise measurement of the anatomy, which could potentially lead to better stent placements.

The MDG forum will be moderated by Dustin Burke, Senior Software Engineer at Aptima. The other speakers will include Scott Stropkay, Partner at Essential Design and Ingolf Tuerk, M.D., Chief of Urology, St. Elizabeth’s Medical Center.

To learn more about this forum and upcoming events, visit [Medical Development Group’s site](#).

###

### **About Corindus Vascular Robotics**

Corindus Vascular Robotics is the global technology leader in robotic-assisted percutaneous coronary interventions (PCIs). The company's FDA-cleared CorPath® 200 System is the first medical device that offers interventional cardiologists PCI procedure control from an interventional cockpit. With the CorPath System, Corindus brings robotic precision to PCI procedures to help optimize clinical outcomes and minimize the costs associated with complications through improper stent placement. Corindus stands behind its technology with a "One Stent Promise," offering a \$1,000 credit to hospitals that use two or more stents per lesion in PCI procedures performed with the CorPath System. For additional information, visit [www.corindus.com](http://www.corindus.com), and follow @CorindusInc.